Kocak et al. defined response to somatostatin analogues (SAs) in acromegaly after surgery considering patients resistant if GH or age-adjusted IGF-1 levels were still elevated after 6 months of therapy with octreotide (40 mg per 28 days) or lanreotide (120 mg per 28 days) [37]. The gene discussed is IGF1; the disease is acromegaly.